Evidence map›Paper›PMID 38893229›Full record

ArticleCancers2024

High-Risk Genotypes of Human Papillomavirus at Diverse Anogenital Sites among Chinese Women: Infection Features and Potential Correlation with Cervical Intraepithelial Neoplasia.

Chao Zhao, Jiahui An, Mingzhu Li, Jingran Li, Yun Zhao, Jianliu Wang, Heidi Qunhui Xie, Lihui Wei

Abstract read
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chao ZhaoDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
Jiahui AnState Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China.
Mingzhu LiDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.ORCID 0000-0002-0937-7862
Jingran LiDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
Yun ZhaoDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
Jianliu WangDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.
Heidi Qunhui XieState Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese Academy of Sciences, Beijing 100085, China.
Lihui WeiDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing 100044, China.ORCID 0000-0002-2478-8790

Funding

Beijing Health Technologies Promotion Program BHTPP2022008National Key Research and Development Program of China 2021YFC2701202
6 · The paper itself

Abstract

backgroundBoth cervical cancer and cervical intraepithelial neoplasia (CIN) are associated with human papillomavirus (HPV) infection at different anogenital sites, but the infection features of high-risk (HR) HPVs at these sites and their association with cervical lesions have not been well characterized. Given the limitation of cervical HPV 16/18 test in screening patients with high-grade CIN (CIN 2+), studies on whether non-16/18 HR-HPV subtype(s) have potential as additional indicator(s) to improve CIN 2+ screening are needed.

methodsThe infection of 15 HR-HPVs in vulva, anus, vagina, and cervix of 499 Chinese women was analyzed, and CIN lesion-associated HR-HPV subtypes were revealed.

resultsIn addition to the well-known cervical-cancer-associated HPV 16, 52, and 58, HPV 51, 53, and 56 were also identified as high-frequency detected subtypes prevalently and consistently present at the anogenital sites studied, preferentially in multi-infection patterns. HPV 16, 52, 58, 56, and 53 were the top five prevalent subtypes in patients with CIN 2+. In addition, we found that cervical HPV 33/35/52/53/56/58 co-testing with HPV 16/18 might improve CIN 2+ screening performance.

conclusionThis study provided a new insight into HR-HPV screening strategy based on different subtype combinations, which might be used in risk stratification clinically.

Indexed as

anogenitalcervical cancerhigh-risk human papillomavirus (HR-HPV)prevalence

Identifiers

PMID38893229
PMCPMC11172096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.